Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 284

1.

Inhibitor development in non-severe haemophilia across Europe.

Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Makris M; EUHASS participants.

Thromb Haemost. 2015 Aug 13;114(4). [Epub ahead of print]

PMID:
26293381
2.

The D173G mutation in ADAMTS-13 causes a severe form of congenital thrombotic thrombocytopenic purpura. A clinical, biochemical andin silico study.

Lancellotti S, Peyvandi F, Pagliari M, Cairo A, Abdel-Azeim S, Edrisse Chermak E, Lazzareschi I, Mastrangelo S, Cavallo L, Oliva R, De Cristofaro R.

Thromb Haemost. 2015 Aug 13;115(1). [Epub ahead of print]

PMID:
26272487
3.

Hypercoagulability Is a Stronger Risk Factor for Ischaemic Stroke than for Myocardial Infarction: A Systematic Review.

Maino A, Rosendaal FR, Algra A, Peyvandi F, Siegerink B.

PLoS One. 2015 Aug 7;10(8):e0133523. doi: 10.1371/journal.pone.0133523. eCollection 2015.

4.

Frequency of the p.Gly262Asp mutation in congenital Factor X deficiency.

Epcacan S, Menegatti M, Akbayram S, Cairo A, Peyvandi F, Oner AF.

Eur J Clin Invest. 2015 Jul 29. doi: 10.1111/eci.12511. [Epub ahead of print]

PMID:
26222694
5.

Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.

Stufano F, Baronciani L, Pagliari MT, Franchi F, Cozzi G, Garcia-Oya I, Bucciarelli P, Boscarino M, Peyvandi F.

J Thromb Haemost. 2015 Jul 23. doi: 10.1111/jth.13062. [Epub ahead of print]

PMID:
26206100
6.

Introducing the Tehran Heart Center's Premature Coronary Atherosclerosis Cohort: THC-PAC Study.

Abbasi SH, Kassaian SE, Sadeghian S, Karimi A, Saadat S, Peyvandi F, Jalali A, Davarpasand T, Shahmansouri N, Lotfi-Tokaldany M, Abchouyeh MA, Isfahani FA, Rosendaal F.

J Tehran Heart Cent. 2015;10(1):34-42. Epub 2015 Jan 8.

7.

Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis.

Maino A, Siegerink B, Lotta LA, Crawley JT, le Cessie S, Leebeek FW, Lane DA, Lowe GD, Peyvandi F, Rosendaal FR.

J Thromb Haemost. 2015 Aug;13(8):1396-404. doi: 10.1111/jth.13032. Epub 2015 Jul 14.

PMID:
26073931
8.

Introduction and overview.

Mannucci PM, Peyvandi F.

Blood Rev. 2015 Jun;29 Suppl 1:S1-3. doi: 10.1016/S0268-960X(15)30001-1. No abstract available.

PMID:
26073364
9.

Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on the fibrinogen γ-module.

Asselta R, Robusto M, Braidotti P, Peyvandi F, Nastasio S, D'Antiga L, Perisic VN, Maggiore G, Caccia S, Duga S.

J Thromb Haemost. 2015 Aug;13(8):1459-67. doi: 10.1111/jth.13021. Epub 2015 Jul 14.

PMID:
26039544
10.

Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation.

Asselta R, Robusto M, Platé M, Santoro C, Peyvandi F, Duga S.

Thromb Res. 2015 Jul;136(1):168-74. doi: 10.1016/j.thromres.2015.05.007. Epub 2015 May 14.

PMID:
26006300
11.

Long-term prophylaxis in severe factor VII deficiency.

Siboni SM, Biguzzi E, Mistretta C, Garagiola I, Peyvandi F.

Haemophilia. 2015 May 8. doi: 10.1111/hae.12702. [Epub ahead of print]

PMID:
25952977
12.

Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia.

Rossio R, Franchi C, Ardoino I, Djade CD, Tettamanti M, Pasina L, Salerno F, Marengoni A, Corrao S, Marcucci M, Peyvandi F, Biganzoli EM, Nobili A, Mannucci PM; REPOSI Investigators.

Eur J Intern Med. 2015 Jun;26(5):330-7. doi: 10.1016/j.ejim.2015.04.002. Epub 2015 Apr 18.

PMID:
25898778
13.

How the direct oral anticoagulant apixaban affects thrombin generation parameters.

Tripodi A, Padovan L, Veena C, Scalambrino E, Testa S, Peyvandi F.

Thromb Res. 2015 Jun;135(6):1186-90. doi: 10.1016/j.thromres.2015.03.032. Epub 2015 Apr 9.

PMID:
25895845
14.

Mediterranean spotted fever and hearing impairment: a rare complication.

Rossio R, Conalbi V, Castagna V, Recalcati S, Torri A, Coen M, Cassulini LR, Peyvandi F.

Int J Infect Dis. 2015 Jun;35:34-6. doi: 10.1016/j.ijid.2015.04.005. Epub 2015 Apr 16.

15.

Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier function.

Pastorelli L, Dozio E, Pisani LF, Boscolo-Anzoletti M, Vianello E, Munizio N, Spina L, Tontini GE, Peyvandi F, Corsi Romanelli MM, Vecchi M.

Gastroenterol Res Pract. 2015;2015:189341. doi: 10.1155/2015/189341. Epub 2015 Feb 12.

16.

Design of clinical trials for new products in hemophilia: communication from the SSC of the ISTH.

Dimichele DM, Lacroix-Desmazes S, Peyvandi F, Srivastava A, Rosendaal FR; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.

J Thromb Haemost. 2015 May;13(5):876-9. doi: 10.1111/jth.12882. Epub 2015 Apr 13. No abstract available.

PMID:
25728341
17.

Rare bleeding disorders: diagnosis and treatment.

Palla R, Peyvandi F, Shapiro AD.

Blood. 2015 Mar 26;125(13):2052-61. doi: 10.1182/blood-2014-08-532820. Epub 2015 Feb 23. Review.

PMID:
25712993
18.

Treatment of Hemophilia in the Near Future.

Peyvandi F, Garagiola I.

Semin Thromb Hemost. 2015 Feb 19. [Epub ahead of print]

PMID:
25703518
19.

Back pain: An old cause in a young adult.

Ferrari B, Rossio R, Peyvandi F.

Eur J Intern Med. 2015 Feb 17. pii: S0953-6205(15)00037-0. doi: 10.1016/j.ejim.2015.02.002. [Epub ahead of print] No abstract available.

PMID:
25701237
20.

Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.

Fischer K, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M; EUHASS participants.

Thromb Haemost. 2015 May;113(5):968-75. doi: 10.1160/TH14-10-0826. Epub 2015 Jan 8.

PMID:
25567324
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk